Literature DB >> 10531573

Cyclosporine A therapy for multisystem langerhans cell histiocytosis.

M Minkov1, N Grois, V Broadbent, A Ceci, A Jakobson, S Ladisch.   

Abstract

BACKGROUND: Treatment of multisystem Langerhans cell histiocytosis (LCH) remains difficult. Various regimens of single and multiagent chemotherapy have been used, but a significant proportion of patients fail to respond to treatment. PROCEDURE: We have evaluated the use of cyclosporine A (CSA) in a controlled group of patients, who had received a systematic primary therapy (LCH-I). Patients received CSA either as a single agent (10 patients) or in combination with vinblastine, etoposide, prednisolone, and/or antithymocyte globulin (16 patients).
RESULTS: Among the total of 26 patients treated, a single patient developed a complete response and three a partial response, whereas 85% (22 patients) had no response to CSA.
CONCLUSIONS: CSA is at best of limited value in the treatment of patients with multisystem LCH, particularly those who had progressive disease while receiving chemotherapy. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10531573     DOI: 10.1002/(sici)1096-911x(199911)33:5<482::aid-mpo8>3.0.co;2-y

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  5 in total

1.  Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

Authors:  Jean Donadieu; Frederic Bernard; Max van Noesel; Mohamed Barkaoui; Odile Bardet; Rosella Mura; Maurizio Arico; Christophe Piguet; Virginie Gandemer; Corinne Armari Alla; Niels Clausen; Eric Jeziorski; Anne Lambilliote; Sheila Weitzman; Jan Inge Henter; Cor Van Den Bos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

2.  Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.

Authors:  Akira Morimoto; Yoko Shioda; Toshihiko Imamura; Kazuko Kudo; Hiroshi Kawaguchi; Kazuo Sakashita; Masahiro Yasui; Yuhki Koga; Ryoji Kobayashi; Eiichi Ishii; Junichiro Fujimoto; Keizo Horibe; Fumio Bessho; Yukiko Tsunematsu; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2016-04-04       Impact factor: 2.490

3.  A rare occurrence of Langerhans cell histiocytosis in an adult.

Authors:  Vruturaj V Shevale; K Ekta; T Snehal; M Geetanjal
Journal:  J Oral Maxillofac Pathol       Date:  2014 Sep-Dec

Review 4.  Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.

Authors:  Caroline Hutter; Milen Minkov
Journal:  Immunotargets Ther       Date:  2016-10-12

5.  Association between Pituitary Langerhans Cell Histiocytosis and Papillary Thyroid Carcinoma.

Authors:  Salvatore Guarino; Deborah Maria Giusti; Antonello Rubini; Pasqualino Favoriti; Cristina Fioravanti; Filippo Maria Di Matteo; Vito D'Andrea; Enrico De Antoni; Antonio Catania
Journal:  Clin Med Insights Case Rep       Date:  2013-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.